Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy
Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.
Factors in Selecting Therapy at First Relapse in Multiple Myeloma
Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.
HER2+ Breast Cancer Treatment Arena May Redefine the Roles of ADCs and Targeted Agents
July 17th 2023Adrienne G. Waks, MD, spotlights the role of the HER2CLIMB regimen in patients with HER2-positive breast cancer with brain metastases, discusses unmet needs in the fourth- and later-line settings in HER2-positive disease, and explains the basis for the ongoing HER2CLIMB-02 and HER2CLIMB-04 trials within the broader ADC landscape.
ADRIATIC Trial and Investigational Treatment Approaches for Limited-Stage SCLC
Faculty discuss potential treatment approaches for limited stage small-cell lung cancer currently under investigation in the ADRIATIC and other ongoing trials.
Combination Therapy Approaches With Chemotherapy and Immunotherapy in ES-SCLC
Panel experts discuss strategies aimed at preventing and managing potential adverse events with first-line combination therapy approaches in extensive stage small-cell lung cancer.
Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC
July 14th 2023Higher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutional cohort of samples from patient with metastatic renal cell carcinoma.
Negative Survival Data From CONTACT-03 Call ICI Rechallenge in Advanced RCC Into Question
July 11th 2023Toni K. Choueiri, MD, highlights findings from the CONTACT-03 trial and their clinical significance, as well as the need for continued investigation of PD-1 inhibitor rechallenge despite the negative trial results with cabozantinib and atezolizumab.
Patient Scenario: Treatment Options in MM at First Relapse
Key opinion leaders review the case of a patient at first relapse with multiple myeloma and consider optimal treatment strategies in this setting.
Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma
A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.
Systemic Therapy Shows Increasing Promise for CNS Metastases in Breast Cancer
July 10th 2023Nancy U. Lin, MD, provides clinical insights on the treatment of patients with breast cancer brain metastases and discusses the advantages and disadvantages of systemic therapy vs radiation therapy for this population.
Expert Insights on First-line Treatment Strategies in SCLC
An overview of first-line treatment options in SCLC with expert insights on important considerations in guiding treatment selection.
CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer
July 8th 2023Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in hormone receptor–positive breast cancer, the future of antibody-drug conjugates in triple-negative breast cancer, and the importance of educating patients about their available treatment options so they can share in the decision-making process.
Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma
Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.
Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Expert perspectives on the treatment armamentarium for transplant-ineligible newly diagnosed multiple myeloma.
Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies
Expert perspectives on the adverse event profiles of first-line combination therapies in the advanced clear cell renal cell carcinoma space.
Dr Sonpavde on the Potential Impact of the THOR Study in FGFR2/3-Altered Urothelial Carcinoma
June 29th 2023Guru P. Sonpavde, MD, discusses the potential impact of the phase 3 THOR study evaluating erdafitinib vs chemotherapy in patients with advanced or metastatic urothelial cancer harboring FGFR2/3 alterations.
Dr Choueiri on the Investigation of ICI Continuation in Advanced RCC
June 28th 2023Toni Choueiri, MD, discusses remaining questions associated with the role of immune checkpoint inhibitor continuation following progression on a prior checkpoint blockade in advanced renal cell carcinoma, and attempts to address them through continued research.
Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma
Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.
Induction Therapy Regimens for Transplant-Eligible NDMM
Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.